Science 37, Inc., the Agile Clinical Trial Operating System, will relocate its corporate headquarters from California to North Carolina’s Research Triangle region and create 250 jobs over five years in Wake County.
Article continues below
>
The company will invest nearly $1.5 million to establish operations in the Town of Morrisville.
Science 37's mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere.
As a pioneer of decentralized clinical trials, the Science 37 Clinical Trial Operating System (OS) supports more agile clinical research designs with its full stack, end-to-end technology platform and specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators and connected devices.
Science 37’s project in Wake County will transition the company’s headquarters from Culver City, California and will create opportunities for administrative, legal, HR, and IT personnel, among other headquarters’ functions.
While salaries will vary based on job roles, the average wage for all the new jobs will be $114,400, which is above the Wake County average of $68,317. The total payroll impact from this project on the region is expected to reach more than $28 million, each and every year.
Science 37’s project in North Carolina will be facilitated by a Job Development Investment Grant (JDIG) approved by the state’s Economic Investment Committee. Over the course of the 12-year term of this grant, the project is estimated to grow the state’s economy by $783 million.
Using a formula that takes into account the new tax revenues generated by the new jobs, the JDIG agreement authorizes the potential reimbursement to the company of up to $3,336,750, spread over 12 years.
State payments only occur following performance verification by the departments of Commerce and Revenue that the company has met its incremental job creation and investment targets. JDIG projects result in positive net tax revenue to the state treasury, even after taking into consideration the grant’s reimbursement payments to a given company. ■